Brewster Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-12-2024
- Paid Up Capital ₹ 30.00 K
as on 06-12-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 517.49%
(FY 2020)
- Profit -36.42%
(FY 2020)
- Ebitda 491.25%
(FY 2020)
- Net Worth 38.75%
(FY 2020)
- Total Assets 40.40%
(FY 2020)
About Brewster Pharma
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 30.00 K , as per Ministry of Corporate Affairs (MCA) records.
Sanjay Raut, Jalinder Pol, Hemant Patil, and Eight other members serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC402264
- Company No.
171995
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Aug 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Brewster Pharma?
Board Members(11)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Raut  | Director | 17-Jan-2022 | Current |
| Jalinder Pol | Director | 18-Sep-2018 | Current |
| Hemant Patil | Director | 02-Jan-2024 | Current |
| Kunal Ghone | Director | 11-Aug-2017 | Current |
| Krishna Galinde | Director | 11-Aug-2017 | Current |
| Amit Patil | Director | 18-Sep-2018 | Current |
Financial Performance of Brewster Pharma.
Brewster Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 517.49% increase. The company also saw a substantial fall in profitability, with a 36.42% decrease in profit. The company's net worth Soared by an impressive increase of 38.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brewster Pharma?
Unlock access to Brewster Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Shriram Ct Scan & Diagnostics Private LimitedActive 11 years 4 months
Kirankumar Nale is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Brewster Pharma?
Unlock and access historical data on people associated with Brewster Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brewster Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brewster Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
